NVL

Across TCGA pan-cancer cohorts, NVL mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NVL data layer compared with 22 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NVL mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NVL expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

CCRCC, LSCC, and LUAD are the cancer types where NVL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.313	0.779	.002	32	view →
LSCC	DFS	Tertile	All	0.926	0.185	<.001	15	view →
LUAD	DFS	Quartile	III,IV	0.944	0.442	.022	7	view →
PDAC	OS	Median	All	0.831	0.858	.024	6	view →
HNSC	DFS	Median	III,IV	0.937	1.000	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NVL–CCRCC (DFS)

Open the CCRCC breakdown →